The ICH Q1 Stability Overhaul: What Changes for Your Stability Program in 2026

Executive summary

The International Council for Harmonisation (ICH) is rewriting the guideline that has governed pharmaceutical stability testing for two decades. On 11 April 2025, the draft ICH Q1, titled Stability Testing of Drug Substances and Drug Products, reached Step 2b of the ICH process and was released for public comment. It is a single, consolidated guideline that replaces the entire legacy Q1A to Q1F series and the biologics-focused Q5C.

The change is larger than a renumbering. The draft extends harmonized stability expectations to synthetic drugs, biologics, vaccines, cell and gene therapies, and combination products under one framework. It introduces stability as a lifecycle activity aligned with ICH Q12, and it builds in science- and risk-based principles drawn from ICH Q8 to Q14. Final adoption is expected in 2026.

For Canadian and cross-border manufacturers, this is the moment to prepare, not react. Health Canada is a standing member of ICH and adopts ICH guidance as official guidance. Stability protocols, bracketing and matrixing strategies, data-evaluation methods, and lifecycle commitments will all need review against the new structure. This article explains what is changing, what stays the same, and the practical steps to ready your stability program.

Introduction

Stability data sit at the centre of every drug submission. They set the shelf life, the storage statement, and the retest period. They support post-approval changes and shelf-life extensions. When stability data are weak, inconsistent, or poorly justified, the consequences show up as deficiency letters, delayed approvals, and inspection findings.

For more than 20 years, the rules lived in a scattered set of documents. Q1A(R2) covered new drug substances and products. Q1B covered photostability. Q1C covered new dosage forms. Q1D covered bracketing and matrixing. Q1E covered how to evaluate the data. Q5C, written separately, covered biotechnological and biological products. Companies had to read across all of them, reconcile overlaps, and reason by analogy for newer product types that none of the documents anticipated.

The new ICH Q1 draft pulls these threads into one modern guideline. It is currently at the draft, or Step 2b, stage. That status matters: the text can still change before it is finalized. But the direction of travel is clear, and waiting until the final version lands leaves little time to redesign protocols that may run for years. Reading the draft now is how you protect future submissions.

What is the ICH Q1 revision?

The purpose of stability testing has not changed. It provides evidence of how the quality of a drug substance or drug product varies over time under the influence of temperature, humidity, light, and other factors, and it supports the assigned shelf life and storage conditions. What is changing is the structure, the scope, and the philosophy.

Structurally, six quality guidelines collapse into one. The new Q1 provides a single reference that applies to all molecule types within its scope, with science- and risk-based principles woven throughout. It is applicable to marketed drug products, including those tied to registration and to lifecycle and post-approval changes, and, where relevant, to drug master files.

Philosophically, the draft moves stability from a fixed checklist toward a justified strategy. It expects you to design a stability program proportionate to the risks of the product and the data, in line with the Quality by Design thinking introduced across ICH Q8 to Q11 and Q14. The same evidence is still required, but you are asked to explain why your approach is fit for purpose.

Why does the ICH Q1 overhaul matter now?

Stability is one of the few areas where the timeline of the science outruns the timeline of the rulebook. Long-term studies commonly run 12, 24, or 36 months. If you start a registration-stability study in 2026 to a protocol built only on Q1A(R2), the data may be evaluated against a finalized ICH Q1 by the time you file. Aligning early avoids redesign, repeat studies, and lost months.

There is also a competitive angle. Companies that understand the consolidated framework can write cleaner protocols, justify reduced designs with confidence, and present extrapolation that holds up. Companies that do not will keep producing data packages built for a world of six separate guidelines, and reviewers will notice.

How Health Canada, the FDA, and the EMA fit in

ICH guidelines become enforceable through regional regulators. The European Medicines Agency opened its consultation on the draft from 30 April 2025 to 30 July 2025. The US Food and Drug Administration announced the draft in the Federal Register on 24 June 2025 under docket FDA-2025-D-1106, with comments due by 25 August 2025. Health Canada, as a standing ICH member, adopts ICH quality guidelines as official guidance once implemented.

Health Canada already implements related lifecycle guidance, including its step-wise adoption of ICH Q12 and Q14. Because ICH Q1 is built to align with Q12, Canadian manufacturers should expect the new stability framework to slot into the lifecycle approach Health Canada is already rolling out.

From six guidelines to one: what is consolidated

The single biggest practical change is consolidation. The table below shows each legacy guideline, what it covered, and its status under the new ICH Q1.

The reintegration of climatic zone guidance is notable. ICH withdrew Q1F in 2006 and left zone III and IV expectations to the World Health Organization and regional authorities. By bringing all climatic zones back into one document, the new Q1 aims at genuine worldwide harmonization, which helps companies that register the same product across many markets.

The new structure: a core guideline plus annexes

The draft separates general principles from technical detail. A core guideline carries the foundational expectations, while annexes hold the more technical and product-specific material. The exact numbering may shift before the final version, but the draft organizes the content along these lines.

The practical message is that detail you once found in standalone guidelines now lives in clearly defined sections. Your protocol templates and standard operating procedures should map to this structure so that nothing is missed and nothing is duplicated.

Stability across the lifecycle: the ICH Q12 connection

Perhaps the most strategic shift is that the draft treats stability as a lifecycle activity rather than a one-time registration exercise. It is written to align with ICH Q12, the guideline on technical and regulatory considerations for product lifecycle management. This means stability is expected to support not only the original filing but also post-approval changes, shelf-life extensions, and ongoing commitments through the life of the product.

For quality teams, the lifecycle framing changes how you plan. Instead of a single registration study, you maintain a living stability strategy: ongoing or annual stability batches, a clear basis for extrapolating shelf life, and pre-defined plans for how a manufacturing or formulation change will be supported by stability data. Established conditions and post-approval change management protocols from Q12 thinking now connect directly to your stability commitments.

Scope expansion: biologics, vaccines, and advanced therapies

The legacy guidelines were written largely for small-molecule, chemically synthesized drugs, with Q5C handling biotech products separately. The new ICH Q1 widens the tent. It is intended to cover both synthetic and biological drug substances and products, including vaccines and other complex biological products, advanced therapy medicinal products such as cell and gene therapies, and combination products that the older documents never addressed.

This is significant for a fast-growing part of the market. Cell and gene therapies, biologics, and drug-device combinations have unique stability challenges, from cold-chain and frozen storage to short shelf lives and complex degradation pathways. Bringing them under a harmonized framework gives developers a clearer reference, while also raising the bar: a justified, risk-based stability strategy is now expected for products that previously relied on case-by-case reasoning.

What stays the same: storage conditions and climatic zones

Not everything is new. The draft retains the familiar storage conditions that stability scientists know well. If your chambers are already set to these conditions, they remain valid.

What expands is the explicit treatment of all climatic zones, including the hot and humid Zone IVB. Because the draft reintegrates the climatic zone guidance once held in the withdrawn Q1F, companies registering products in tropical and subtropical markets gain a single harmonized reference rather than a patchwork of regional rules.

Reduced designs: bracketing and matrixing

Bracketing and matrixing let you test fewer samples without losing confidence in the result, which saves time and laboratory cost. Bracketing tests only the extremes of factors such as strength or container size, on the assumption that the extremes represent the middle. Matrixing tests a planned subset of samples across time points, rotating which samples are tested when.

Under the new Q1, these reduced designs remain available, but the expectation to justify them is sharper. A matrix must be applied per storage condition and should not mix unrelated test attributes. A bracketing design must rest on a sound assumption that the bracketed extremes truly bound the behaviour of the intermediate variants. The reduced-design annex consolidates this guidance so your statistical rationale and your protocol can be reviewed together.

The same applies to data evaluation. The stability-modelling annex builds on the former Q1E approach to extrapolating a shelf life beyond the period of long-term data. If you intend to claim a 24-month shelf life from 12 months of data, the statistical justification must be defensible. Done well, modelling shortens time to market. Done poorly, it invites a deficiency.

What this means for your stability program

The redesign work falls into a few clear areas. First, your stability protocols and templates need to map to the consolidated structure, so a single master protocol references the core guideline and the relevant annexes rather than citing six separate documents. Second, your bracketing and matrixing rationales should be rewritten to meet the sharper justification expectations, with the statistical basis documented up front.

Third, your shelf-life extrapolation and modelling approach should be reviewed against the modelling annex so that claims are statistically sound. Fourth, if you handle biologics, vaccines, or advanced therapies, you now have a harmonized reference and should align your product-specific stability strategies to it. Fifth, your lifecycle commitments, including ongoing stability and post-approval change protocols, should be connected to the Q12 lifecycle approach. Each of these is a discrete, manageable project if it starts now.

Stability program readiness checklist

Use this checklist to structure a gap assessment of your stability program against the draft ICH Q1.

• Read the draft. Obtain the Step 2b ICH Q1 text and identify where it differs from the guidelines your SOPs currently cite.
• Inventory active and planned studies. List every stability study running or planned through 2026 and 2027 that could be reviewed against a finalized ICH Q1.
• Remap protocol templates. Update master stability protocols to reference the core guideline and annex structure rather than the legacy Q1A to Q1F and Q5C citations.
• Rebuild reduced-design rationales. Document the statistical justification for each bracketing and matrixing design, per storage condition.
• Review extrapolation and modelling. Confirm shelf-life claims beyond the long-term data period are defensible under the modelling annex.
• Align biologics and ATMP strategies. Map vaccine, biologic, and advanced-therapy stability plans to the new harmonized scope.
• Connect stability to the lifecycle. Link ongoing stability and post-approval change protocols to your ICH Q12 lifecycle commitments.
• Confirm storage conditions and zones. Verify chamber conditions and climatic-zone coverage for every market you supply.
• Coordinate analytical methods. Ensure stability-indicating methods are validated and ready, with the laboratory aligned to the protocol schedule.
• Train the team. Brief stability, QA, and regulatory staff on the consolidated framework before the final guideline is adopted.

Common mistakes to avoid

• Waiting for the final text before acting. Stability studies are long. A protocol written today may be judged against the finalized ICH Q1, so design with the draft in view now.
• Treating consolidation as a simple renumbering. The draft changes how you justify designs and evaluate data, not just where the rules live.
• Applying a small-molecule mindset to biologics and ATMPs. The expanded scope brings these products under a harmonized standard that expects a justified, risk-based strategy.
• Using reduced designs without a documented basis. Bracketing and matrixing must rest on a sound, written statistical rationale that survives review.
• Over-reaching on extrapolation. Claiming a long shelf life from limited data without defensible modelling is a frequent source of deficiencies.
• Ignoring the lifecycle link. Stability that supports only the original filing, with no plan for post-approval change, misses the intent of the new framework.

How does the ICH Q1 overhaul affect compliance and inspections?

Direct answer: Once ICH Q1 is finalized and adopted, reviewers and inspectors will expect stability data packages that follow the consolidated structure and show a justified, risk-based strategy. The most likely weak points are unjustified reduced designs, extrapolation that the data do not support, stability strategies for biologics or ATMPs that lack a clear rationale, and SOPs that still cite withdrawn or superseded guidelines.

Inspection readiness rests on traceability. For each product, you should be able to show the protocol, the rationale for any reduced design, the basis for the assigned shelf life, the validation status of the stability-indicating methods, and the lifecycle commitments that follow approval. A corrective and preventive action (CAPA) system should already be catching and resolving stability deviations, out-of-specification results, and trend signals.

The strongest position is a current gap assessment that compares your live stability procedures against the draft ICH Q1, with a dated remediation plan. That single document signals to a reviewer or inspector that your organization understands the coming standard and is managing the transition deliberately rather than reactively.

How MFLRC can help

MF License and Regulatory Consultants (MFLRC) helps pharmaceutical, biologic, and natural health product companies design stability programs that are technically sound and defensible under review. Our quality assurance services include stability program design, protocol writing, and coordination with contract analytical laboratories, so your studies are built right from the start.

• Stability gap assessments that compare your current protocols and SOPs against the draft ICH Q1, with a prioritized remediation roadmap.
• Stability protocol and master-plan development, including bracketing and matrixing rationales and shelf-life extrapolation strategy.
• Analytical method coordination and validation services so your stability-indicating methods are ready and reliable.
• Audit and inspection-readiness support through our audit services, including mock audits and CAPA review for stability systems.
• Lifecycle and submission strategy through our regulatory affairs and licensing team, across pharmaceuticals and the wider regulated life-sciences sector.

If you are also preparing for other ICH changes, see our companion guide on ICH E6(R3) readiness in Canada.

Need help redesigning your stability program for ICH Q1? Book a stability readiness review with MFLRC for expert guidance tailored to your products.

Frequently asked questions

What is ICH Q1?

ICH Q1 is the International Council for Harmonisation guideline on stability testing of drug substances and drug products. The 2025 draft is a consolidated revision that replaces the former Q1A to Q1F series and the Q5C biologics guideline with a single document covering all molecule types within its scope.

When was the new ICH Q1 draft released?

The draft reached Step 2b of the ICH process on 11 April 2025 and was released for public comment. The EMA consultation ran from 30 April to 30 July 2025, and the FDA announced the draft in the Federal Register on 24 June 2025. Final adoption is expected in 2026.

Which guidelines does ICH Q1 replace?

It consolidates Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C. The climatic zone content of Q1F, which ICH withdrew in 2006, is reintegrated so that all climatic zones are covered in one harmonized guideline.

Does ICH Q1 apply to biologics and cell and gene therapies?

Yes. The draft expands scope to both synthetic and biological products, including vaccines, other complex biologics, advanced therapy medicinal products such as cell and gene therapies, and combination products that the older guidelines did not address.

Are the storage conditions changing under ICH Q1?

The core storage conditions are retained: long-term at 25°C / 60% RH, intermediate at 30°C / 65% RH, and accelerated at 40°C / 75% RH. The draft adds explicit, harmonized treatment of all climatic zones, including hot and humid markets.

How does ICH Q1 relate to ICH Q12?

The draft treats stability as a lifecycle activity aligned with ICH Q12. Stability data are expected to support not only the original registration but also post-approval changes and shelf-life management across the life of the product.

When will ICH Q1 apply in Canada?

ICH Q1 is still a draft and is expected to be finalized in 2026. Health Canada is a standing ICH member and adopts ICH quality guidelines as official guidance once implemented, so Canadian manufacturers should prepare now and confirm the implementation date with Health Canada as it is announced.

Conclusion

The ICH Q1 overhaul is the most significant change to pharmaceutical stability testing in 20 years. Six scattered guidelines become one. The scope grows to include biologics, vaccines, and advanced therapies. Stability becomes a lifecycle activity tied to ICH Q12, and the whole framework leans on science- and risk-based justification rather than a fixed checklist.

Because the draft is still at Step 2b, there is time to prepare, but not time to waste. Stability studies are long, and a finalized ICH Q1 in 2026 will set the standard your future submissions are measured against. The companies that read the draft now, run a gap assessment, and redesign protocols deliberately will treat adoption as a routine milestone. Those that wait may discover the gap between their data and the new standard at the worst possible moment, during review or inspection. A focused readiness review today is the most efficient path to a confident transition.

Sources and references

European Medicines Agency. ICH Q1 guideline on stability testing of drug substances and drug products (Step 2b draft). ema.europa.eu

US Food and Drug Administration. Q1 Stability Testing of Drug Substances and Drug Products, Draft Guidance for Industry (docket FDA-2025-D-1106). fda.gov

US Federal Register. Q1 Stability Testing of Drug Substances and Drug Products; ICH; Draft Guidance Availability (24 June 2025). federalregister.gov

ICH. Quality Guidelines. ich.org

Health Canada. International Council for Harmonisation (ICH) guidelines. canada.ca

This article is for general information and does not constitute regulatory or legal advice. ICH Q1 is a draft and may change before it is finalized. Regulatory requirements change. Confirm current obligations with Health Canada and qualified advisors before making compliance decisions.